Home›The Library›Metreleptin
Metreleptin
Metreleptin (Myalept) is a real, FDA-approved recombinant leptin analog for generalized lipodystrophy, a rare disease where the body can't produce enough of its own leptin — approved on open-label evidence rather than a placebo-controlled trial, and carrying a boxed warning for both antibody formation and lymphoma.
On this page
In brief
Should you care? Relevant only if generalized lipodystrophy is relevant to you or someone you know — an ultra-rare disease, not a wellness product.The short version
- A recombinant analog of leptin, the hormone adipose tissue normally produces — lipodystrophy patients lack the fat tissue to make enough of their own.
- Approved February 2014 on open-label NIH studies rather than a placebo-controlled trial, since withholding treatment from a severely metabolically ill population raised real ethical concerns.
- Boxed warning for anti-drug antibody formation and lymphoma risk — available only through a REMS program.
What lipodystrophy is, and why leptin replacement helps
Generalized lipodystrophy is a rare disease in which patients lack sufficient adipose (fat) tissue — and since fat tissue is what normally produces leptin, they're also severely leptin-deficient. That deficiency drives serious metabolic complications: severe insulin resistance, diabetes, very high triglycerides, and fatty liver disease. Metreleptin is a recombinant analog of human leptin (methionyl-leptin), replacing what these patients' bodies can't make enough of.
The approval: real evidence, an unusual pathway
The FDA approved metreleptin (as Myalept) on 25 February 2014 for adjunct-to-diet treatment of complications of leptin deficiency in congenital or acquired generalized lipodystrophy — the first and only FDA-approved therapy for this indication. Unlike most drug approvals, this one rested on open-label, uncontrolled NIH investigator-sponsored studies rather than a randomized placebo-controlled trial — a real, deliberate departure from the usual evidence bar, driven by the ethical difficulty of withholding treatment from a small population with severe, disfiguring metabolic disease. An earlier proof-of-concept study (Oral et al., N Engl J Med 2002, PMID 11856796) treated 9 patients and found improved glycemic control and reduced triglycerides. The EU approved a broader indication in 2018 (as Myalepta), covering partial as well as generalized lipodystrophy in patients 12 and older — a wider label than the US version.
The boxed warning
Metreleptin carries an FDA boxed warning with two distinct components. First, anti-metreleptin antibodies with neutralizing activity have been identified in treated patients, associated in trial data with severe infections and worsening metabolic control in some cases. Second, T-cell lymphoma has been reported in patients with acquired generalized lipodystrophy, both treated and untreated with metreleptin — meaning the underlying disease itself may carry some baseline lymphoma risk independent of the drug, a nuance worth being precise about rather than assuming pure drug-causation. Because of these risks, metreleptin in the US is available only through a REMS (Risk Evaluation and Mitigation Strategy) program.
Current status
Still marketed; current ownership sits with Chiesi (which acquired the Myalept/Myalepta assets via its 2023 acquisition of Amryt Pharma). No evidence found of metreleptin being sold on grey-market or bodybuilding-adjacent sites — consistent with the biology (leptin signals satiety and suppresses appetite, not a performance-enhancing effect anyone is chasing) and its REMS-controlled specialty-pharmacy distribution.
References
- Oral EA, Simha V, Ruiz E, et al., "Leptin-Replacement Therapy for Lipodystrophy," N Engl J Med 2002;346(8):570-578, PMID 11856796, DOI: 10.1056/NEJMoa012437.
- FDA approval history for Myalept (metreleptin), 25 February 2014.